Skip to content
2000
Volume 15, Issue 11
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450115666140908125738
2014-10-01
2025-06-07
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450115666140908125738
Loading

  • Article Type:
    Research Article
Keyword(s): Crohn’s disease; early disease; inflammatory bowel disease; therapy
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test